- Home
- BLRX vs NVNO Comparison
BLRX vs NVNO Comparison
Compare BLRX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- NVNO
- Stock Information
- Founded
- BLRX 2003
- NVNO 1987
- Country
- BLRX Israel
- NVNO United States
- Employees
- BLRX N/A
- NVNO N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- BLRX Health Care
- NVNO Health Care
- Exchange
- BLRX Nasdaq
- NVNO Nasdaq
- Market Cap
- BLRX 17.1M
- NVNO 16.7M
- IPO Year
- BLRX 2011
- NVNO N/A
- Fundamental
- Price
- BLRX $3.50
- NVNO $0.72
- Analyst Decision
- BLRX Strong Buy
- NVNO
- Analyst Count
- BLRX 2
- NVNO 0
- Target Price
- BLRX $19.00
- NVNO N/A
- AVG Volume (30 Days)
- BLRX 29.2K
- NVNO 316.7K
- Earning Date
- BLRX 11-24-2025
- NVNO 10-31-2025
- Dividend Yield
- BLRX N/A
- NVNO N/A
- EPS Growth
- BLRX N/A
- NVNO N/A
- EPS
- BLRX N/A
- NVNO N/A
- Revenue
- BLRX $17,251,000.00
- NVNO N/A
- Revenue This Year
- BLRX N/A
- NVNO N/A
- Revenue Next Year
- BLRX N/A
- NVNO N/A
- P/E Ratio
- BLRX N/A
- NVNO N/A
- Revenue Growth
- BLRX 1.19
- NVNO N/A
- 52 Week Low
- BLRX $2.30
- NVNO $0.67
- 52 Week High
- BLRX $22.60
- NVNO $5.62
- Technical
- Relative Strength Index (RSI)
- BLRX 37.77
- NVNO 31.95
- Support Level
- BLRX $3.51
- NVNO $0.68
- Resistance Level
- BLRX $3.89
- NVNO $0.76
- Average True Range (ATR)
- BLRX 0.24
- NVNO 0.06
- MACD
- BLRX -0.04
- NVNO 0.03
- Stochastic Oscillator
- BLRX 0.00
- NVNO 18.99
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.